Pfizer CEO predicts cancer drugs as the next big breakthrough. Josh Brown boosts his Pfizer holdings. Investors face a dilemma: should they prioritize Pfizer's reliable high yields or Merck's promising growth? With Pfizer stock at a 52-week low, now's the time to dig deep into the stock analysis and make a smart investment choice.